A Multicenter, Open-Label, Single-Arm Study of YONDELIS (Trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment

Trial Profile

A Multicenter, Open-Label, Single-Arm Study of YONDELIS (Trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Ewing's sarcoma; Osteosarcoma; Soft tissue sarcoma
  • Focus Adverse reactions; Expanded access
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 12 Sep 2017 Results of a retrospective analysis assessing the efficacy and safety of trabectedin in an elderly patient subgroup with advanced leiomyosarcoma (LMS) or liposarcoma, presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results (n=1803) of retrospective analysis assessing efficacy and safety of patients treated long-term with trabectedin on the expanded access program, were presented at the 42nd European Society for Medical Oncology Congress.
    • 17 Nov 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top